Zobrazeno 1 - 10
of 499
pro vyhledávání: '"CM Perou"'
Autor:
E Sahin, Purba Singh, M Leng, B-J Kim, MJ Ellis, Airi Han, Jonathan T. Lei, Ryoichi Matsunuma, Chun-Yang Fan, Anna Malovannaya, Chonghui Cheng, Alexander B. Saltzman, CM Perou, Doug W. Chan
Publikováno v:
Cancer Research. 79:P5-08
Proteogenomics is the field of integrating data from mass spectrometry-based shotgun proteomics, and phosphoproteomics into next-generation RNA and DNA sequencing data analysis pipelines that promises new insights into cancer biology and therapeutic
Autor:
Lyndsay Harris, Lisa A. Carey, Ian E. Krop, Sara M. Tolaney, Maki Tanioka, Chau T. Dang, M-Y Polley, EP Winer, Donald A. Berry, Joel Parker, CM Perou, LN Henry
Publikováno v:
Cancer Research. 79:P3-08
Background: In CALGB 40601 (Alliance, NCT00770809), a neoadjuvant phase III trial of paclitaxel and trastuzumab with or without lapatinib for 12 weeks for patients with HER2-positive breast cancer, 33% of pretreatment tumors were Luminal A subtype, h
Autor:
CM Perou, Ian Hurley, Tatyana A. Grushko, O. I. Olopade, Galina Khramtsova, Ashley Hardeman, W Clayton, Joel S. Parker
Publikováno v:
Cancer Research. 79:P3-07
This abstract was not presented at the conference. Citation Format: Hardeman A, Grushko T, Clayton W, Hurley I, Khramtsova G, Parker J, Perou C, Olopade O. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 201
Autor:
JM Dixon, Lorna Renshaw, Lee Murphy, Jonine D. Figueroa, Lisa A. Carey, Andrew H. Sims, Maki Tanioka, Arran K Turnbull, Cigdem Selli, J Keys, Xiaping He, Angie Fawkes, Carlos Martinez-Perez, R Clark, A Coutts, A Fernando, CM Perou, Alison F. Munro
Publikováno v:
Cancer Research. 79:P3-06
Background: Transcriptomic analyses of clinical samples can help improve our understanding of disease aetiology, drug effectiveness, assign molecular subtypes and derive prognostic signatures for clinical decision-making. The success of early microar
Autor:
Trevor A. Jolly, Rachel C. Jankowitz, Hyman B. Muss, Claire Dees, Dominic T. Moore, Oludamilola Olajide, Maria J. Sambade, KE Reeder-Hayes, Rebecca Kaltman, Luz Cuaboy, CM Perou, Kristen Cowens, Carey K. Anders, Lisa A. Carey, J.S. Serody, Dante S. Bortone, Mark Woodcock, Benjamin C. Calhoun, Amy Garrett, Benjamin G. Vincent, Karen P. McKinnon, Vinay K. Gudena
Publikováno v:
Cancer Research. 79:P2-09
Background: While immunotherapy holds promise in the treatment of mTNBC, response rates (RR) in unselected patients (pts) are approximately 20%. Strategies to augment response to immunotherapy include depletion of regulatory T cells (Tregs). A single
Autor:
J. Cortes, Lisa A. Carey, Sonia Pernas, Maki Tanioka, MV Dieci, Laia Paré, Joaquín Gavilá, Antonio Llombart, Patricia Galván, Marcos Vinicius Silva Oliveira, Pierfranco Conte, Aleix Prat, V Guarnieri, CM Perou, T. Pascual
Publikováno v:
Cancer Research. 78:P2-09
Background. HER2+/HR+ BC is heterogeneous and subgroups with different treatment sensitivities need to be identified. We previously reported a PAM50-based CES in HR+/HER2-negative BC (Prat et al. CCR 2016). Here, we evaluated the association of CES w
Autor:
Jianfang Liu, Lori A. Sturtz, O. I. Olopade, Peter W. Laird, Hai Hu, Craig D. Shriver, Katherine A. Hoadley, GB Mills, Carl Simon Shelley, Suhn K. Rhie, Eric R. Gamazon, Jason J. Pitt, Andrew D. Cherniack, Toshio F. Yoshimatsu, CM Perou, Yuanbin Ru, Dezheng Huo, Melissa A. Troester, Tara M. Lichtenberg
Publikováno v:
Cancer Research. 77:P1-05
Background: African American breast cancer patients have worse survival rates than European American patients. Although racial differences in the distribution of breast cancer intrinsic subtype are known, it is unclear if there are other inherent gen
Autor:
C-K Tse, Henry Shelton Earp, Erin L. Kirk, MB Bell, KE Reeder-Hayes, Xuezheng Sun, CM Perou, Lisa A. Carey, Linnea T. Olsson, Melissa A. Troester, Andrew F. Olshan
Publikováno v:
Cancer Research. 78:P6-08
Compared with white women, black women have higher breast cancer mortality. Racial differences have been reported in frequency of PAM50 intrinsic subtypes, and PAM50 intrinsic subtype is associated with prognosis. However, there is a paucity of data
Autor:
Elisa R. Port, Deborah Collyar, R Qamar, Jennifer R. Bellon, Sara M. Tolaney, EP Winer, William M. Sikov, K Sturtz, Lisa A. Carey, CM Perou, C. Cirrincione, George Somlo, Olwen Hahn, Baljit Singh, Clifford A. Hudis, Eleftherios P. Mamounas, Mehra Golshan, Donald A. Berry
Publikováno v:
Cancer Research. 76:S2-05
Background: CALGB (Alliance) 40603 measured the effects of adding carboplatin (Cb) and/or bevacizumab (Bev) to standard neoadjuvant chemotherapy (weekly paclitaxel x 12 then doxorubicin/cyclophosphamide every 2 weeks x 4) on pathologic complete respo
Autor:
Nadine Norton, EA Thompson, CM Perou, Jennifer M. Carr, E. A. Perez, Mcu Cheang, Afshin Mashadi-Hossein, Jennifer M. Kachergus, Kathleen S. Tenner, Brian M. Necela, Karla V. Ballman, Sean Ferree
Publikováno v:
Cancer Research. 76:P3-07
Importance: 20-25% of patients with early stage HER2-positive breast cancer develop tumor relapse after adjuvant trastuzumab. Identification of such patients is a key goal for clinical management decisions. Objective: To assess molecular heterogeneit